

AMENDMENT

U.S. Appln. No. 09/428,458

subject in need of said inhibition, a pharmaceutical composition comprising:

- ¹D
- (A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and
 - (B) a pharmaceutically acceptable adjuvant or filler.
-

Claim 45. (Amended) A method of treating a subject afflicted with an immunosuppressive disease, comprising administering to said subject a pharmaceutical composition comprising:

- ²D
- (A) a pharmaceutically effective amount of a cAMP antagonist sufficient to treat an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type I α isozyme (RI α ₂C₂); and
 - (B) a pharmaceutically acceptable adjuvant or filler.
-

³D

Claim 47. (Amended) The method of Claim 45, wherein said cAMP antagonist is a thio-substituted cAMP analog, wherein said thio-substituted cAMP analog is an equatorial diastereomer of 3',5'-cyclic adenosine monophosphorothioate (Rp-cAMPS), and wherein said thio-substituted cAMP analog binds to an RI α subunit of said isozyme and acts as a selective or specific antagonist of said isozyme.
